| Drug Name |
Trimetrexate |
| Drug ID |
BADD_D02292 |
| Description |
A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against pneumocystis pneumonia in AIDS patients. Myelosuppression is its dose-limiting toxic effect. |
| Indications and Usage |
For use, with concurrent leucovorin administration (leucovorin protection), as an alternative therapy for the treatment of moderate-to-severe Pneumocystis carinii pneumonia (PCP) in immunocompromised patients, including patients with the acquired immunodeficiency syndrome (AIDS). Also used to treat several types of cancer including colon cancer. |
| Marketing Status |
approved; investigational |
| ATC Code |
P01AX07 |
| DrugBank ID |
DB01157
|
| KEGG ID |
D06238
|
| MeSH ID |
D016597
|
| PubChem ID |
5583
|
| TTD Drug ID |
D0Y7TS
|
| NDC Product Code |
Not Available |
| UNII |
UPN4ITI8T4
|
| Synonyms |
Trimetrexate | JB-11 | JB 11 | JB11 | Trimetrexate Monohydrate, Monoacetate | Monohydrate, Monoacetate Trimetrexate | NSC-328564 | NSC 328564 | NSC328564 | Trimetrexate Hydrate | Hydrate, Trimetrexate | CI-898 | CI 898 | CI898 | NSC-249008 | NSC 249008 | NSC249008 |
